[go: up one dir, main page]

MX336865B - Imidazopiridazinas como inhibidores de quinasa akt. - Google Patents

Imidazopiridazinas como inhibidores de quinasa akt.

Info

Publication number
MX336865B
MX336865B MX2013011699A MX2013011699A MX336865B MX 336865 B MX336865 B MX 336865B MX 2013011699 A MX2013011699 A MX 2013011699A MX 2013011699 A MX2013011699 A MX 2013011699A MX 336865 B MX336865 B MX 336865B
Authority
MX
Mexico
Prior art keywords
imidazopyridazines
kinase inhibitors
akt kinase
akt
inhibitors
Prior art date
Application number
MX2013011699A
Other languages
English (en)
Other versions
MX2013011699A (es
Inventor
Roland Neuhaus
Hartmut Rehwinkel
Hans Briem
Ulf Bömer
Lars Bärfacker
William Johnston Scott
Andrea Hägebarth
Stuart Ince
Oliver Politz
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MX2013011699A publication Critical patent/MX2013011699A/es
Publication of MX336865B publication Critical patent/MX336865B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Imidazopiridazinas de fórmula (I), (Ver Formula) un proceso para su producción y el uso las mismas.
MX2013011699A 2011-04-07 2012-04-05 Imidazopiridazinas como inhibidores de quinasa akt. MX336865B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161472732P 2011-04-07 2011-04-07
PCT/EP2012/056300 WO2012136776A1 (en) 2011-04-07 2012-04-05 Imidazopyridazines as akt kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2013011699A MX2013011699A (es) 2014-01-31
MX336865B true MX336865B (es) 2016-02-04

Family

ID=45953129

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011699A MX336865B (es) 2011-04-07 2012-04-05 Imidazopiridazinas como inhibidores de quinasa akt.

Country Status (43)

Country Link
US (2) US9206185B2 (es)
EP (1) EP2694510B1 (es)
JP (1) JP5906303B2 (es)
KR (1) KR20140022057A (es)
CN (1) CN103596957B (es)
AP (1) AP3597A (es)
AR (1) AR087148A1 (es)
AU (1) AU2012238589B2 (es)
BR (1) BR112013025777A2 (es)
CA (1) CA2832374A1 (es)
CL (1) CL2013002878A1 (es)
CO (1) CO6862145A2 (es)
CR (1) CR20130515A (es)
CU (1) CU24263B1 (es)
CY (1) CY1117163T1 (es)
DK (1) DK2694510T3 (es)
DO (1) DOP2013000226A (es)
EA (1) EA024890B1 (es)
EC (1) ECSP13013008A (es)
ES (1) ES2558780T3 (es)
GT (1) GT201300238A (es)
HR (1) HRP20160011T1 (es)
HU (1) HUE026323T2 (es)
IL (1) IL228567A0 (es)
JO (1) JO3068B1 (es)
MA (1) MA35016B1 (es)
ME (1) ME02316B (es)
MX (1) MX336865B (es)
NI (1) NI201300105A (es)
PE (1) PE20141380A1 (es)
PH (1) PH12013502073A1 (es)
PL (1) PL2694510T3 (es)
PT (1) PT2694510E (es)
RS (1) RS54480B1 (es)
SG (1) SG193631A1 (es)
SI (1) SI2694510T1 (es)
SM (1) SMT201600001B (es)
TN (1) TN2013000400A1 (es)
TW (1) TWI535719B (es)
UA (1) UA111739C2 (es)
UY (1) UY34006A (es)
WO (1) WO2012136776A1 (es)
ZA (1) ZA201307223B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3289876T (lt) 2008-06-16 2022-11-10 University Of Tennessee Research Foundation Junginiai, skirti vėžio gydymui
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
JP5879273B2 (ja) 2010-03-01 2016-03-08 ジーティーエックス・インコーポレイテッド 癌を処置するための化合物
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
HUE026323T2 (en) * 2011-04-07 2016-05-30 Bayer Ip Gmbh Imidazopyridazines as akt kinase inhibitors
EP2802588B1 (en) * 2012-01-10 2016-05-25 Bayer Intellectual Property GmbH Substituted pyrazolopyrimidines as akt kinase inhibitors
ES2588186T3 (es) * 2012-01-10 2016-10-31 Bayer Intellectual Property Gmbh Imidazopirazinas sustituidas como inhibidores de la quinasa Akt
IL300664A (en) * 2012-11-30 2023-04-01 Novartis Ag Innovative pharmaceutical composition
MX375059B (es) * 2013-03-05 2025-03-06 Univ Tennessee Res Found Compuestos para el tratamiento de cancer.
WO2014158467A1 (en) * 2013-03-12 2014-10-02 Glaxosmithkline Llc Combination
AU2014236348B2 (en) * 2013-03-14 2018-05-10 Epizyme, Inc. Combination therapy for treating cancer
EP3092242A1 (en) * 2014-01-09 2016-11-16 Bayer Pharma Aktiengesellschaft Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders
MA46888A (fr) * 2016-11-28 2021-06-02 Bristol Myers Squibb Co Inhibiteurs de gsk-3
EP3453706A1 (en) 2017-09-08 2019-03-13 Basf Se Pesticidal imidazole compounds
GB2600384A (en) 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2393724A1 (en) 1999-12-23 2001-06-28 Nitromed, Inc. Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
ATE361297T1 (de) 2000-03-31 2007-05-15 Ortho Mcneil Pharm Inc Phenyl-substituierte imidazopyridine
DE60112272T2 (de) 2000-04-27 2006-05-24 Astellas Pharma Inc. Imidazopyridin-derivate
KR20050122210A (ko) 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
AU2004233828B2 (en) 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
EP1660500B1 (en) 2003-07-30 2007-12-12 Laboratorios S.A.L.V.A.T., S.A. Substituted imidazopyrimidines for the prevention and treatment of cancer
US7655649B2 (en) 2004-04-09 2010-02-02 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
CN101217958A (zh) 2004-08-23 2008-07-09 默克公司 Akt活性抑制剂
EP1786780A1 (de) 2004-08-24 2007-05-23 Basf Aktiengesellschaft Imidazolium-methylsulfite als ausgangsverbindungen zur herstellung ionischer flüssigkeiten
EP1827436A4 (en) 2004-12-15 2011-08-10 Merck Sharp & Dohme INHIBITORS OF ACT ACTIVITY
WO2006125101A2 (en) 2005-05-20 2006-11-23 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
AU2006258124B8 (en) 2005-06-10 2010-01-07 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
US7530313B2 (en) 2006-05-12 2009-05-12 Day & Zimmerman, Inc. Self-destruct fuze delay mechanism
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
MX2009013213A (es) * 2007-06-08 2010-03-30 Abbott Lab Indazoles 5-sustituidos 5-heteroarilo como inhibidores de cinasa.
CL2008002397A1 (es) 2007-08-14 2009-09-25 Bayer Schering Pharma Ag Compuestos derivados de imidazoles biciclicos fusionados; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar neoplasia benigna o maligna.
PT2188291E (pt) 2007-08-14 2012-12-20 Bayer Ip Gmbh Pirimidinas bicíclicas fundidas
WO2009086130A1 (en) 2007-12-21 2009-07-09 Wyeth Imidazo [1,2-b] pyridazine compounds as modulators of liver x receptors
WO2009148887A1 (en) 2008-06-03 2009-12-10 Merck & Co., Inc. Inhibitors of akt activity
JP2011522048A (ja) 2008-06-03 2011-07-28 メルク・シャープ・エンド・ドーム・コーポレイション Akt活性の阻害剤
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
JP2012516847A (ja) 2009-02-02 2012-07-26 メルク・シャープ・エンド・ドーム・コーポレイション Akt活性の阻害剤
CA2752105C (en) * 2009-02-13 2017-10-31 Matthias Vennemann Fused pyrimidines
WO2010104933A1 (en) 2009-03-11 2010-09-16 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
AR076936A1 (es) 2009-06-02 2011-07-20 Vitae Pharmaceuticals Inc Inhibidores de carbamato y urea de la 11 beta hidroxiesteroide deshidrogenasa 1
EP2473495A1 (en) * 2009-09-18 2012-07-11 Almac Discovery Limited Pharmaceutical compounds
EP2593451B1 (en) * 2010-07-12 2015-08-19 Bayer Intellectual Property GmbH Substituted imidazo[1,2-a]pyrimidines and -pyridines
ES2539257T3 (es) * 2010-07-28 2015-06-29 Bayer Intellectual Property Gmbh Imidazo[1,2-b]piridazinas sustituidas
HUE026323T2 (en) * 2011-04-07 2016-05-30 Bayer Ip Gmbh Imidazopyridazines as akt kinase inhibitors

Also Published As

Publication number Publication date
AU2012238589B2 (en) 2017-02-16
EP2694510A1 (en) 2014-02-12
CA2832374A1 (en) 2012-10-11
DK2694510T3 (en) 2016-01-18
EA024890B1 (ru) 2016-10-31
CR20130515A (es) 2013-12-04
JO3068B1 (ar) 2017-03-15
KR20140022057A (ko) 2014-02-21
US20140113901A1 (en) 2014-04-24
TW201245204A (en) 2012-11-16
US9604989B2 (en) 2017-03-28
EP2694510B1 (en) 2015-10-14
MA35016B1 (fr) 2014-04-03
GT201300238A (es) 2015-04-06
US20150368250A1 (en) 2015-12-24
HRP20160011T1 (hr) 2016-02-12
ES2558780T3 (es) 2016-02-08
CO6862145A2 (es) 2014-02-10
PE20141380A1 (es) 2014-10-18
CY1117163T1 (el) 2017-04-05
SMT201600001B (it) 2016-02-25
EA201301130A1 (ru) 2014-07-30
WO2012136776A1 (en) 2012-10-11
CN103596957A (zh) 2014-02-19
HUE026323T2 (en) 2016-05-30
US9206185B2 (en) 2015-12-08
BR112013025777A2 (pt) 2016-12-20
AP2013007215A0 (en) 2013-10-31
UA111739C2 (uk) 2016-06-10
AP3597A (en) 2016-02-19
UY34006A (es) 2012-10-31
JP5906303B2 (ja) 2016-04-20
SI2694510T1 (sl) 2016-02-29
NI201300105A (es) 2014-07-14
JP2014510127A (ja) 2014-04-24
NZ616270A (en) 2015-09-25
MX2013011699A (es) 2014-01-31
TWI535719B (zh) 2016-06-01
CU20130135A7 (es) 2014-02-28
PL2694510T3 (pl) 2016-03-31
IL228567A0 (en) 2013-12-31
AR087148A1 (es) 2014-02-26
DOP2013000226A (es) 2013-11-15
AU2012238589A1 (en) 2013-11-07
SG193631A1 (en) 2013-11-29
ME02316B (me) 2016-06-20
ZA201307223B (en) 2014-12-23
PT2694510E (pt) 2016-02-08
CN103596957B (zh) 2016-12-07
ECSP13013008A (es) 2013-12-31
PH12013502073A1 (en) 2014-01-13
TN2013000400A1 (en) 2015-03-30
RS54480B1 (sr) 2016-06-30
CL2013002878A1 (es) 2014-05-02
CU24263B1 (es) 2017-07-04

Similar Documents

Publication Publication Date Title
TN2013000400A1 (en) Imidazopyridazines as akt kinase inhibitors
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
PH12014500373A1 (en) Amino quinazolines as kinase inhibitors
EP2566477A4 (en) AMINO-QUINOLINES AS KINASE INHIBITORS
MX339873B (es) Inhibidores de serina/treonina cinasa.
GEP201706745B (en) Forms of rifaximin and usage thereof
PH12013500554A1 (en) Process for preparing pan-cdk inhibitors of the formula (i) and intermediates in the preparation
PH12015500363A1 (en) Prodrugs of amino quinazoline kinase inhibitor
MX370649B (es) Proceso para la preparacion de teneligliptina.
NZ711192A (en) Process for making benzoxazepin compounds
GEP201706626B (en) Synthesis of (s)-nifuratel
MX2012014796A (es) Proceso para preparar 4-hidroxipiridinas.
EP2882744B8 (en) Process for the preparation of c-fms kinase inhibitors
GB201107985D0 (en) Process
AU2013314244A8 (en) Novel inhibitor compounds of phosphodiesterase type 10A
NZ720805A (en) Processes for the preparation of pyrimidinylcyclopentane compounds
AU2013347232A8 (en) 3-Aminocyclopentane carboxamide derivatives
MX348841B (es) Derivados de pirimidooxazocina como inhibidores de mtor.
IN2014DN07191A (es)
TN2013000128A1 (en) Process for preparing pan-cdk inhibitors of the formula (1), and intermediates in the preparation
PH12013501279A1 (en) New process for the synthesis of agomelatine
UA77456U (ru) Способ профилактики гингивита
TN2011000020A1 (en) cMET INHIBITORS

Legal Events

Date Code Title Description
FG Grant or registration